Biogen-IDEC (BIIB +4.1%) closes at the top of the S&P leader board after ISI Group ups it to...


Biogen-IDEC (BIIB +4.1%) closes at the top of the S&P leader board after ISI Group ups it to Buy, citing a strong pipeline, and noting its new BG-12 multiple-sclerosis pill can double earnings over the next three to four years.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs